同時型腎細胞癌與攝護腺癌和繼發型腎細胞癌與攝護腺癌的預後比較 - 單一中心研究

林佳瑜、徐明蔚¹、楊啟瑞¹、張兆祥¹、吳錫金¹、黃志平¹、陳冠亨¹、陳汶吉¹

中國醫藥大學附設醫院 教學部，¹泌尿部

Prognosis of Synchronous Renal Cell Carcinoma and Prostate Cancer compared to Metachronous Renal Cell Carcinoma and Prostate Cancer – a single center experience
Chia-Yu Lin, Ming-Wei Hsu¹, Chi-Rei Yang¹, Chao-Hsiang Chang¹, Hsi-Chin Wu¹, Chi-Ping Huang¹, Guan-Heng Chen¹, Wen-Chi Chen¹

Department of Teaching and Urology¹, China Medical University Hospital, Taichung, Taiwan

Purpose:

Renal cell carcinoma and prostate cancer are common urological malignancies. However, synchronous renal cell carcinoma and prostate cancer is uncommon and there was no related analysis to date. Treatment of synchronous urinary tract malignancies is challenging due to its different oncological nature and unfamiliar clinical scenario We aim to investigated the clinical characteristics and oncologic outcomes of this scenario in our center.

Materials and Methods:

We identified 30 patients with concurrent renal cell carcinoma and prostate cancer in the China Medical University Hospital spanning from 2009 to 2023. These patients were categorized into synchronous group (n= 14) and metachronous group (n=16). We examined their individual characteristics and assessed both overall survival and progression-free survival.

Results:

In cases of metachronous renal cell carcinoma and prostate cancer, 13 patients were initially diagnosed with renal cell carcinoma followed by prostate cancer (81.3%), while 3 patients were initially diagnosed with prostate cancer followed by renal cell carcinoma (18.7%). There was higher incidence of high-risk prostate cancer (p=0.029) and advanced renal cell carcinoma (p=0.07) in synchronous group than metachronous group. The overall survival was shorter in synchronous group (mean OS 164 months vs 112.4 months, p=0.041) while there was no significant difference in progression-free survival between the two groups (mean PFS 124.3 months vs 143.5 months, p=0.484).

Conclusions:

There was greater occurrence of renal cell carcinoma with subsequent prostate cancer than prostate cancer with subsequent renal cell carcinoma. Our analysis suggests that synchronous renal cell carcinoma and prostate cancer has a more unfavorable prognosis than metachronous renal cell carcinoma and prostate cancer. Overall, the median overall survival could reach 10 years. With advancements in diagnostic tools, we anticipate a rise in future cases.